Immunotech Laboratories, Inc. (Immunotech) is a drug development company that focuses on research and development in the biotechnology field. The Company is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 11:32:22 19/10/2026 pm IST			5-day change	1st Jan Change
0.000200 ^USD	0.00%		0.00%	+100.00%

22/17/22	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
22/17/22	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI

Market Cap	60.56L 54.33L 50.23L 45.49L 84.99L 58Cr 86.02L 6.01Cr 2.39Cr 30Cr 2.27Cr 2.22Cr 96Cr	P/E 2008 *	-	P/E 2009	-310x
Enterprise Value	72.46L 65.01L 60.11L 54.44L 1.02Cr 69Cr 1.03Cr 7.19Cr 2.86Cr 36Cr 2.72Cr 2.66Cr 114.65Cr	EV / Sales 2008 *	-	EV / Sales 2009	-
Free-Float	99.34%	Yield 2008 *	-	Yield 2009	-

22/17/22	Immunotech Laboratories, Inc. Announces Addition of Hongxiang Hui to Advisory Board	CI
22/17/22	Immunotech Laboratories Enters Distribution Agreement for the Territory of the Ukraine; Enters Final Step of Full Commercialization by the BDA Post Phase 3 Approval of ITV-1 for HIV/AIDS	CI
14/17/14	Eco-Petroleum Solutions, Inc. acquired Immunotech Laboratories, Inc..	CI
01/16/01	Immunotech Laboratories, Inc. cancelled the transaction announced on October 1, 2013	CI
21/14/21	Ebola becomes latest stock scam, SEC says	RE
21/14/21	Immunotech Laboratories, Inc. and Immunotech Laboratories, BG Enter into Agreement with Uldic Investment to Market Potential Ebola Virus Disease Treatment in Africa	CI
07/14/07	Immunotech Laboratories, Inc and Immunotech Laboratories, BG. Announces Successful Completion of Phase I and Phase II Field Trials of HIV/AIDS and Hepatitis C Virus Treatment	CI
28/14/28	Immunotech Laboratories, Inc. Announces Completion of Phase I and Phase II Field Trials of Patented Treatment of the HIV/AIDS and Hepatitis C Viruses	CI
01/13/01	Immunotech Laboratories, Inc. announced that it expects to receive funding from World Finance Capital Holdings Inc.	CI
15/13/15	Immunotech Laboratories, Inc. Appoints Blaine Nabors as VP of Business Development	CI
01/13/01	Immunotech Laboratories, Inc. Relocates to New Research & Development Laboratory Facility	CI
21/13/21	Immunotech Laboratories, Inc. Announces Clinical Trials Updates for company's AIDS-HIV 'IPF' Medicines	CI
05/13/05	Immunotech Laboratories, Inc. Appoints Valentin Dimitrov to Board of Directors	CI

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.01
10 years	0		0.09

Immunotech Laboratories, Inc. Share Price

Stocks

IMMB

US45254F2039

Biotechnology & Medical Research

Valuation: Immunotech Laboratories, Inc.

Chart: Immunotech Laboratories, Inc.

Latest news: Immunotech Laboratories, Inc.

Press Releases: Immunotech Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Immunotech Laboratories, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Director	Title	Age	Since
Harry Zhabilov CHM	Chairman	59	01/07/2014
Valentin Dimitrov BRD	Director/Board Member	61	04/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOTECH LABORATORIES, INC.	0.00%	0.00%	+100.00%	0.00%	1L
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	6.41TCr
ARGENX SE	+1.23%	+2.94%	+12.53%	+84.36%	5.55TCr
LONZA GROUP AG	+1.52%	+1.50%	+12.73%	+104.69%	5.3TCr
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	4.6TCr
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	4.25TCr
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	4.04TCr
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	3.23TCr
GENMAB A/S	-2.62%	+42.09%	+102.85%	+89.40%	3.45TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-0.44%	+23.18%	-10.77%	2.42TCr
Average	+0.48%	+3.67%	+56.96%	+146.19%	3.93TCr
Weighted average by Cap.	+0.82%	+3.49%	+49.24%	+160.41%

	*	1 *
Net sales	-	-
Net income	-	-
Net Debt	-	-